Sensei Biotherapeutics: StemPoint reports 9.9% stake

Sensei Biotherapeutics reports a joint Schedule 13G filing disclosing a 9.9% stake.

Rhea-AI Filing Summary

Sensei Biotherapeutics reports a joint Schedule 13G filing disclosing a 9.9% stake. The filing states that StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross may be deemed beneficial owners of 132,873 shares of Common Stock. Shares outstanding were 1,340,281 as of March 23, 2026, per the company’s Form 10-K cited in the filing. The Reporting Persons disclose shared voting power of 116,587 and shared dispositive power of 132,873.

Insights

Institutional Ownership Analyst

Joint filing shows a near-10% position by StemPoint and an affiliated individual.

The filing lists 132,873 shares beneficially owned and a 9.9% ownership stake calculated on March 23, 2026. Voting and dispositive powers are disclosed as shared rather than sole, indicating collective control within the reporting group.

Key dependencies include the March 30, 2026 Form 10-K share count used for the percentage and the joint-filing agreement. Subsequent Schedule 13D/13G amendments would be the document to watch for changes in ownership or intent.

Corporate Governance Specialist

Disclosure highlights shared control and a joint filing structure rather than unilateral authority.

The cover data show shared voting power: 116,587 and shared dispositive power: 132,873. The joint filing cites StemPoint entities and Michelle Ross as Reporting Persons under Rule 13d-1(k).

This filing is informational under Schedule 13G; any material change in intentions or plans would normally be reflected in an amendment or a Schedule 13D if the group takes an activist stance.

Key Figures

Shares beneficially owned: 132,873 shares Percent of class: 9.9% Shares outstanding: 1,340,281 shares +2 more

5 metrics

Shares beneficially owned 132,873 shares Amount reported as beneficially owned by the Reporting Persons

Percent of class 9.9% Ownership percentage calculated using the issuer's outstanding shares

Shares outstanding 1,340,281 shares Shares outstanding as of <date>March 23, 2026</date> per the issuer's Form 10-K

Shared voting power 116,587 shares Amount of shares with shared voting power disclosed on the cover pages

Shared dispositive power 132,873 shares Amount of shares with shared dispositive power disclosed on the cover pages

Key Terms

Schedule 13G, beneficially owned, shared dispositive power, joint filing agreement

4 terms

Schedule 13G regulatory

"This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Each Reporting Person may be deemed to be the beneficial owner of 132,873 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 132,873.00"

joint filing agreement regulatory

"JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake did StemPoint report in Sensei Biotherapeutics (SNSE)?

StemPoint and affiliates reported beneficial ownership of 132,873 shares, representing 9.9% of outstanding common stock. The percentage is calculated using 1,340,281 shares outstanding as of March 23, 2026 per the cited Form 10-K.

Who are the Reporting Persons on the Schedule 13G for SNSE?

The Schedule 13G is jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross. A joint‑filing agreement is included and signatures appear from the reporting group.

How much voting power does the reporting group disclose in the filing?

The filing discloses shared voting power of 116,587 shares and shared dispositive power of 132,873 shares. Sole voting or dispositive power is reported as 0 for each Reporting Person.

What share count did the filing use to calculate the 9.9% ownership?

The filing states the 9.9% calculation is based on 1,340,281 shares outstanding as of March 23, 2026, cited from the issuer’s Form 10-K filed on March 30, 2026.

Does the Schedule 13G indicate control by a single person?

No. The filing shows shared voting and dispositive powers across the reporting entities, indicating collective rather than sole control of the disclosed shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:00 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Sensei Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

81728A207

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

StemPoint Capital LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 116,587.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 132,873.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

132,873.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

StemPoint Capital Management GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 116,587.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 132,873.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

132,873.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Michelle Ross

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 116,587.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 132,873.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

132,873.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sensei Biotherapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1405 Research Boulevard, Suite 125, Rockville, MD 20850
Item 2.
(a)	Name of person filing: This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person").
(b)	Address or principal business office or, if none, residence: The business addresses of each Reporting Person is: 520 Madison Avenue, 19th Floor New York, NY 10022
(c)	Citizenship: StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware. StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware. Michelle Ross is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP Number(s): 81728A207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 132,873 shares of Common Stock.
(b)	Percent of class: Each Reporting Person may be deemed to beneficially own 9.9% shares of Common Stock, which is calculated based on 1,340,281 Shares outstanding of Common Stock as of March 23, 2026, as reported in the Issuer's report on Form 10-K for the annual period ended December 31, 2025 filed with the SEC on March 30, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: -0-
	(ii) Shared power to vote or to direct the vote: 116,587.
	(iii) Sole power to dispose or to direct the disposition of: -0-
	(iv) Shared power to dispose or to direct the disposition of: 132,873.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

StemPoint Capital LP

Signature:	/s/ Sean C. Tan
Name/Title:	Sean C. Tan, Authorized Signatory
Date:	05/15/2026

StemPoint Capital Management GP LLC

Signature:	/s/ Sean C. Tan
Name/Title:	Sean C. Tan, Authorized Signatory
Date:	05/15/2026

Michelle Ross

Signature:	/s/ Michelle Ross
Name/Title:	Michelle Ross
Date:	05/15/2026

Exhibit Information

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)